Interim estimates of influenza vaccine effectiveness in 2012/13 from Canada’s sentinel surveillance network, January 2013

Introduction Rapid Point of Care Testing (POCT) for influenza could be used to provide information on influenza vaccine effectiveness (IVE) as well as influencing clinical decision-making in primary care. Methods We undertook a test negative case control study to estimate the overall and age-specific (6 months-17 years, 18–64 years, ≥65 years old) IVE against medically attended POCT-confirmed influenza. The study took place over the winter of 2019–2020 and was nested within twelve general practices that are part of the Oxford-Royal College of General Practitioners (RCGP) Research and Surveillance Centre (RSC), the English sentinel surveillance network. Results 648 POCT were conducted. 193 (29.7%) of those who were swabbed had received the seasonal influenza vaccine. The crude unadjusted overall IVE was 46.1% (95% CI: 13.9–66.3). After adjusting for confounders the overall IVE was 26.0% (95% CI: 0–65.5). In total 211 patients were prescribed an antimicrobial after swab testing. Given a positive influenza POCT result, the odds ratio (OR) of receiving an antiviral was 21.1 (95%CI: 2.4–182.2, p = <0.01) and the OR of being prescribed an antibiotic was 0.6 (95%CI: 0.4–0.9, p = <0.01). Discussion Using influenza POCT in a primary care sentinel surveillance network to estimate IVE is feasible and provides comparable results to published IVE estimates. A further advantage is that near patient testing of influenza is associated with improvements in appropriate antiviral and antibiotic use. Larger, randomised studies are needed in primary care to see if these trends are still present and to explore their impact on outcomes.

Download Full-text

Interim estimates of 2013/14 vaccine effectiveness against influenza A(H1N1)pdm09 from Canada’s sentinel surveillance network, January 2014

Eurosurveillance ◽

10.2807/1560-7917.es2014.19.5.20690 ◽

2014 ◽

Vol 19 (5) ◽

Cited By ~ 30

Author(s):

D M Skowronski ◽

C Chambers ◽

S Sabaiduc ◽

G De Serres ◽

J A Dickinson ◽

...

Keyword(s):

Influenza A ◽

Vaccine Effectiveness ◽

Sentinel Surveillance ◽

Surveillance Network ◽

Binary File ◽

Influenza A H1n1

Binary file ES_Abstracts_Final_ECDC.txt matches

Download Full-text

Influenza Vaccine Effectiveness and Waning Effect in Hospitalized Older Adults. Valencia Region, Spain, 2018/2019 Season

International Journal of Environmental Research and Public Health ◽

10.3390/ijerph18031129 ◽

2021 ◽

Vol 18 (3) ◽

pp. 1129

Author(s):

Ainara Mira-Iglesias ◽

F. Xavier López-Labrador ◽

Javier García-Rubio ◽

Beatriz Mengual-Chuliá ◽

Miguel Tortajada-Girbés ◽

...

Keyword(s):

Older Adults ◽

Influenza Vaccine ◽

Influenza A ◽

Vaccine Effectiveness ◽

Surveillance Network ◽

Adjuvanted Vaccine ◽

Clinical Registries ◽

Populations At Risk ◽

Influenza A H1n1 ◽

Hospitalized Older Adults

Influenza vaccination is annually recommended for specific populations at risk, such as older adults. We estimated the 2018/2019 influenza vaccine effectiveness (IVE) overall, by influenza subtype, type of vaccine, and by time elapsed since vaccination among subjects 65 years old or over in a multicenter prospective study in the Valencia Hospital Surveillance Network for the Study of Influenza and other Respiratory Viruses (VAHNSI, Spain). Information about potential confounders was obtained from clinical registries and/or by interviewing patients and vaccination details were only ascertained by registries. A test-negative design was performed in order to estimate IVE. As a result, IVE was estimated at 46% (95% confidence interval (CI): (16%, 66%)), 41% (95% CI: (−34%, 74%)), and 45% (95% CI: (7%, 67%)) against overall influenza, A(H1N1)pdm09 and A(H3N2), respectively. An intra-seasonal not relevant waning effect was detected. The IVE for the adjuvanted vaccine in ≥75 years old was 45% (2%, 69%) and for the non-adjuvanted vaccine in 65–74 years old was 59% (−16%, 86%). Thus, our data revealed moderate vaccine effectiveness against influenza A(H3N2) and not significant against A(H1N1)pdm09. Significant protection was conferred by the adjuvanted vaccine to patients ≥75 years old. Moreover, an intra-seasonal not relevant waning effect was detected, and a not significant IVE decreasing trend was observed over time.

Download Full-text

Early estimates of seasonal influenza vaccine effectiveness in Europe, 2010/11: I-MOVE, a multicentre case–control study

Eurosurveillance ◽

10.2807/ese.16.11.19818-en ◽

2011 ◽

Vol 16 (11) ◽

Cited By ~ 23

Author(s):

E Kissling ◽

M Valenciano ◽

Collective I-MOVE case–control studies team

Keyword(s):

Influenza Vaccine ◽

Seasonal Influenza ◽

Case Control Study ◽

Case Control ◽

Vaccine Effectiveness ◽

Seasonal Influenza Vaccine ◽

Binary File ◽

Control Study

Binary file ES_Abstracts_Final_ECDC.txt matches

Download Full-text

2741. Seasonal Influenza Vaccine Timing in Children and Adults Hospitalized with Influenza in the United States, FluSurv-NET, 2013–2017

Open Forum Infectious Diseases ◽

10.1093/ofid/ofz360.2418 ◽

2019 ◽

Vol 6 (Supplement_2) ◽

pp. S964-S965

Author(s):

Julia C Haston ◽

Shikha Garg ◽

Angela P Campbell ◽

Jill Ferdinands ◽

Alissa O’Halloran ◽

...

Keyword(s):

Influenza Vaccine ◽

Seasonal Influenza ◽

Patient Characteristics ◽

Risk Groups ◽

The United States ◽

Vaccine Effectiveness ◽

Chi Square ◽

Surveillance Network ◽

Seasonal Influenza Vaccine ◽

Hispanic Patients

Abstract Background Seasonal influenza vaccine may attenuate disease severity among people infected with influenza despite vaccination, but vaccine effectiveness may decrease with increasing time between vaccination and infection. Patient characteristics may play a role in the timing of vaccine receipt. Methods We used data from the Influenza Hospitalization Surveillance Network (FluSurv-NET) and included patients ≥ 9 years hospitalized with laboratory-confirmed influenza during October 1–April 30 of influenza seasons 2013–2014 through 2016–2017 who received seasonal influenza vaccine ≥ 14 days prior to admission. Vaccine history was obtained from vaccine registries, medical charts, and patient interviews. We defined “early vaccination” as vaccine receipt before October 15 and “late vaccination” as receipt after (date selected using typical season onset and median vaccination dates). Early and late groups were compared using Chi-square or Fisher exact tests. Results Among 21,751 vaccinated patients, 61% received vaccine before October 15, and distribution of vaccination date was similar across seasons (figure). Vaccination occurred earlier with increasing age (45% were vaccinated early among those 9–17 years but 65% in those ≥ 80 years, P < 0.01). White non-Hispanic patients were more likely to receive vaccine early compared with black non-Hispanic and Hispanic patients (63% vs. 55% and 54%; P < 0.01). Those with metabolic disorders, cardiovascular disease, kidney disease, and cancer were vaccinated earlier whereas those with HIV and liver disease were vaccinated later. Vaccine timing also varied by state (P < 0.01) but not by sex. Conclusion Among influenza-vaccinated older children and adults hospitalized with influenza, older age, white race, and certain medical conditions were associated with early receipt of influenza vaccination in unadjusted analysis. This may be due to frequent healthcare encounters and targeted public health strategies in high-risk groups. Understanding how timing of vaccine receipt varies among populations can provide insights into variables that must be controlled for in studying possible vaccine effectiveness waning and attenuation of disease among those who are infected despite vaccination. Disclosures All authors: No reported disclosures.

Download Full-text

Influenza epidemiology and influenza vaccine effectiveness during the 2015–2016 season: results from the Global Influenza Hospital Surveillance Network

BMC Infectious Diseases ◽

10.1186/s12879-019-4017-0 ◽

2019 ◽

Vol 19 (1) ◽

Cited By ~ 5

Author(s):

Joan Puig-Barberà ◽

◽

Ainara Mira-Iglesias ◽

Elena Burtseva ◽

Benjamin J. Cowling ◽

...

Keyword(s):

Influenza Vaccine ◽

Vaccine Effectiveness ◽

Surveillance Network

Download Full-text

Influenza epidemiology and influenza vaccine effectiveness during the 2016–2017 season in the Global Influenza Hospital Surveillance Network (GIHSN)

BMC Public Health ◽

10.1186/s12889-019-6713-5 ◽

2019 ◽

Vol 19 (1) ◽

Cited By ~ 6

Author(s):

Víctor Baselga-Moreno ◽

◽

Svetlana Trushakova ◽

Shelly McNeil ◽

Anna Sominina ◽

...

Keyword(s):

Influenza Vaccine ◽

Vaccine Effectiveness ◽

Surveillance Network

Download Full-text

Interim estimates of 2014/15 vaccine effectiveness against influenza A(H3N2) from Canada’s Sentinel Physician Surveillance Network, January 2015

Eurosurveillance ◽

10.2807/1560-7917.es2015.20.4.21022 ◽

2015 ◽

Vol 20 (4) ◽

Cited By ~ 68

Author(s):

D M Skowronski ◽

C Chambers ◽

S Sabaiduc ◽

G De Serres ◽

J A Dickinson ◽

...

Keyword(s):

Influenza A ◽

Vaccine Effectiveness ◽

Surveillance Network ◽

Binary File

Binary file ES_Abstracts_Final_ECDC.txt matches

Download Full-text

Interim estimates of 2019/20 vaccine effectiveness during early-season co-circulation of influenza A and B viruses, Canada, February 2020

Eurosurveillance ◽

10.2807/1560-7917.es.2020.25.7.2000103 ◽

2020 ◽

Vol 25 (7) ◽

Cited By ~ 6

Author(s):

Danuta M Skowronski ◽

Macy Zou ◽

Suzana Sabaiduc ◽

Michelle Murti ◽

Romy Olsha ◽

...

Keyword(s):

Confidence Interval ◽

Influenza Vaccine ◽

Influenza A ◽

Vaccine Effectiveness ◽

Influenza B ◽

Surveillance Network ◽

Early Season ◽

Influenza Illness

Interim results from Canada's Sentinel Practitioner Surveillance Network show that during a season characterised by early co-circulation of influenza A and B viruses, the 2019/20 influenza vaccine has provided substantial protection against medically-attended influenza illness. Adjusted VE overall was 58% (95% confidence interval (CI): 47 to 66): 44% (95% CI: 26 to 58) for A(H1N1)pdm09, 62% (95% CI: 37 to 77) for A(H3N2) and 69% (95% CI: 57 to 77) for influenza B viruses, predominantly B/Victoria lineage.

Download Full-text